Strategies for Treatment of Thyroid Cancer

被引:4
|
作者
Yadav, Deepika [1 ]
Sharma, Pramod Kumar [1 ]
Malviya, Rishabha [1 ]
Mishra, Prem Shankar [1 ]
机构
[1] Galgotias Univ, Sch Med & Allied Sci, Dept Pharm, Greater Noida, Uttar Pradesh, India
关键词
Thyroid cancer; radioactive iodine; molecular therapy; ablation treatment; thyroidectomy; novel target therapy; RET/PTC ONCOGENE ACTIVATION; PHASE-II TRIAL; RET PROTOONCOGENE; PAPILLARY CARCINOMAS; CURRENT DIAGNOSIS; KINASE INHIBITOR; HIGH-FREQUENCY; RAS; REARRANGEMENTS; TUMORS;
D O I
10.2174/1389450124666230222093308
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
More people are diagnosed with thyroid cancer than any other endocrine tumor. Differentiated thyroid cancer is often treated by removing the thyroid gland (thyroidectomy), iodizing radiation, or inhibiting thyroid stimulating hormone (TSH). Advanced thyroid carcinomas are notoriously resistant to chemotherapy, thus the pursuit of alternative treatments is vital. The best methods for treating individuals with advanced nonmedullary and medullary thyroid carcinomas are discussed in this post. Numerous tyrosine kinase inhibitors and antiangiogenic inhibitors, two types of novel target therapy, have shown promise in studies for individuals with thyroid cancer. Both the positive and unfavourable outcomes of clinical studies of these drugs were addressed. The findings presented here are encouraging, but more study is required to establish whether or not this method is effective in the treatment of thyroid cancer.
引用
收藏
页码:406 / 415
页数:10
相关论文
共 50 条
  • [1] Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer
    Walgama, Evan
    Busaidy, Naifa
    Zafereo, Mark
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2022, 51 (02) : 379 - 389
  • [2] Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
    Worden, Francis
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (06) : 267 - 279
  • [3] Update on Fundamental Mechanisms of Thyroid Cancer
    Prete, Alessandro
    de Souza, Patricia Borges
    Censi, Simona
    Muzza, Marina
    Nucci, Nicole
    Sponziello, Marialuisa
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [4] Diagnosis and Treatment of Patients with Thyroid Cancer
    Nguyen, Quang T.
    Lee, Eun Joo
    Huang, Melinda Gingman
    Park, Young In
    Khullar, Aashish
    Plodkowski, Raymond A.
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (01) : 30 - 38
  • [5] Vandetanib for the treatment of thyroid cancer: an update
    Karras, Spyridon
    Anagnostis, Panagiotis
    Krassas, Gerasimos E.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (03) : 469 - 481
  • [6] Carcinogenesis and Therapeutic Strategies in Thyroid Cancer
    Liu, Zhi-Min
    Wu, Ting-Ting
    van Hasselt, C. Andrew
    Chen, George G.
    CURRENT DRUG TARGETS, 2010, 11 (06) : 716 - 732
  • [7] New Developments in the Diagnosis and Treatment of Thyroid Cancer
    Schneider, David F.
    Chen, Herbert
    CA-A CANCER JOURNAL FOR CLINICIANS, 2013, 63 (06) : 373 - 394
  • [8] Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer
    Karras, Spyridon
    Pontikides, Nikolaos
    Krassas, Gerasimos E.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (04) : 507 - 515
  • [9] Treatment of refractory thyroid cancer
    Berdelou, Amandine
    Lamartina, Livia
    Klain, Michele
    Leboulleux, Sophie
    Schlumberger, Martin
    ENDOCRINE-RELATED CANCER, 2018, 25 (04) : R209 - R223
  • [10] Treatment of advanced thyroid cancer: role of molecularly targeted therapies
    Covell, Lorinda L.
    Ganti, Apar Kishor
    TARGETED ONCOLOGY, 2015, 10 (03) : 311 - 324